Skip to main content
    Q

    Qiagen NV (QGEN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $49.75
    -0.06 (-0.12%)

    Market Cap: $10.29B

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Qiagen NV (QGEN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Qiagen NV (QGEN) has a market cap of $10.29B and an enterprise value of $11.12B. Its share count is down 4.76% from a year earlier. Its return on invested capital of 8.20% compares with a 3.09% median across 8 similar companies.

    Total Valuation

    Enterprise value is 8.14% above the market cap, as debt exceeds cash.

    Market Cap$10.29B
    Enterprise Value$11.12B
    Latest price (Nov 17, 2026)$49.75

    Key Dates

    The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Jul 7, 2026.

    Next Earnings DateFeb 2, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Last Ex-Dividend DateJul 7, 2026
    Last Payment DateJul 14, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.11% in the quarter ended Sep 30, 2026 and shrank 3.63% a year over 2 years.

    Shares Outstanding208.06M
    Shares Change (YoY)-4.76%
    Shares Change (QoQ)+0.11%
    Share Count Growth (2Y CAGR)-3.63%

    Valuation Ratios

    Sales and book value multiples are 4.9x and 3.0x. Its year-end P/E ranged from 18.2x to 23.0x from 2016 to 2025.

    P/E Ratio20.5x
    Forward P/E19.8x
    P/S Ratio4.9x
    Forward P/S4.8x
    P/B Ratio3.0x
    P/TBV Ratio22.2x
    P/FCF Ratio23.8x
    P/OCF Ratio16.2x
    PEG Ratio3.3

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 15.9x EBITDA and 25.8x free cash flow.

    EV / Earnings28.9x
    EV / Sales5.3x
    EV / EBITDA15.9x
    EV / EBIT22.2x
    EV / FCF25.8x

    Price Statistics

    The stock is up 11.68% over 52 weeks and trades 6.35% above its 50-day average.

    Beta (1Y)0.40
    52-Week Change+11.68%
    1-Month Change+6.87%
    3-Month Change+11.80%
    6-Month Change+46.61%
    5-Year Change-9.94%
    10-Year Change+105.99%
    Total Return (1Y)+17.61%
    Total Return (3Y CAGR)+8.07%
    Total Return (5Y CAGR)-2.38%
    Return vs SPY (1Y)+0.04%
    Max Drawdown (1Y)-41.90%
    Max Drawdown (3Y)-41.90%
    Sharpe Ratio (1Y)0.32
    Correlation with SPY (1Y)0.16
    50-Day Average$46.78
    200-Day Average$42.24
    52-Week Range$32.24 to $57.30
    RSI (14 Days)58.7
    Average Volume (20 Days)6.31M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.63x current liabilities, and total debt is 0.47x shareholder equity.

    Current Ratio2.63x
    Quick Ratio2.14x
    Debt / Equity0.47x
    Debt / EBITDA2.33x
    Debt / FCF3.78x
    Interest Coverage12.02x

    Returns and Efficiency

    Return on invested capital is 8.20% over the last 12 months, against a 5-year average of 6.95%.

    Return on Equity (ROE)11.08%
    Return on Assets (ROA)6.48%
    Return on Invested Capital (ROIC)8.20%
    Return on Capital Employed (ROCE)9.48%
    ROE (5Y Average)10.26%
    ROA (5Y Average)5.77%
    ROIC (5Y Average)6.95%
    Asset Turnover0.34x
    Inventory Turnover2.52x
    Receivables Turnover5.36x
    Cash Conversion Cycle170 days

    Taxes

    Income tax took 16.21% of pretax income over the last 12 months.

    Income Tax (TTM)$74.48M
    Effective Tax Rate16.21%

    Scores

    QGEN has an Altman Z-Score of 4.05, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score4.05
    Altman Z ZoneSafe
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $2.12B over the last 12 months is up 2.17% from the 12 months before.

    Revenue$2.12B
    Revenue Growth (YoY)+2.17%
    Gross Profit$1.32B
    Operating Income$554.57M
    Pretax Income$459.42M
    Net Income$384.93M
    EBITDA$705.36M
    EBIT$501.12M
    Reported EPS (TTM)$2.43

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 58.42% of the $5.94B in total assets.

    Cash and Equivalents$805.13M
    Total Debt$1.64B
    Net Debt$837.72M
    Net Debt Per Share$4.03
    Working Capital$1.07B
    Shareholder Equity$3.47B
    Book Value Per Share$16.70
    Tangible Book Value$465.88M
    Tangible Book Per Share$2.24
    Total Assets$5.94B
    Total Liabilities$2.47B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $200.76M of capital spending, operating cash flow left $434.32M of free cash flow.

    Operating Cash Flow$635.08M
    Capital Expenditures$200.76M
    Free Cash Flow$434.32M
    FCF Per Share$2.10
    Depreciation and Amortization$204.24M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 26.21%, against a 5-year average of 20.70%.

    Gross Margin62.45%
    Operating Margin26.21%
    Pretax Margin21.72%
    Net Margin18.19%
    EBITDA Margin33.34%
    EBIT Margin23.69%
    FCF Margin20.53%
    Gross Margin (5Y Average)60.51%
    Operating Margin (5Y Average)20.70%
    Net Margin (5Y Average)16.89%

    Growth

    Revenue fell 0.81% a year over 3 years, and EPS 2.19% a year.

    Revenue Growth (3Y CAGR)-0.81%
    Revenue Growth (5Y CAGR)+2.25%
    EPS Growth (3Y CAGR)-2.19%
    EPS Growth (5Y CAGR)+0.58%
    FCF Growth (3Y CAGR)-7.13%
    FCF Growth (5Y CAGR)+19.24%
    Operating Income Growth (3Y CAGR)-0.70%
    Book Value Per Share Growth (2Y CAGR)+3.39%
    Tangible Book Per Share Growth (2Y CAGR)-3.84%

    Revenue and profit by year

    Dividends and Yields

    QGEN pays out 18.92% of earnings as dividends.

    Dividend Per Share (Annual)$0.35
    Dividend Yield0.70%
    Payment ScheduleAnnual
    Payout Ratio18.92%
    Earnings Yield4.88%
    FCF Yield4.20%
    Shareholder Yield4.04%

    Stock Splits

    The last split was a 4-for-1 forward split on Jul 14, 2000.

    Last Split DateJul 14, 2000
    Split TypeForward split
    Split Ratio4:1

    Peer Position

    Against 10 similar companies, QGEN has the 10th highest P/E.

    P/E Ratio20.5x vs 33.8x median
    P/S Ratio4.9x vs 4.8x median
    ROIC8.20% vs 3.09% median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.17% vs +10.11% median
    Dividend Yield0.70% vs 0.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 3.65% and EPS growth at 3.94% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+3.65%
    EPS Growth Forecast (2Y CAGR)+3.94%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About QGEN

    What is QGEN's market cap?

    Qiagen NV has a market cap of $10.29B. Its enterprise value, which adds debt and subtracts cash, is $11.12B.

    What is QGEN's P/E ratio?

    Qiagen NV has a trailing P/E ratio of 20.5x and a forward P/E of 19.8x.

    How many shares of QGEN are outstanding?

    Qiagen NV has 208.06M shares outstanding. The count is down 4.76% from a year earlier.

    Does QGEN pay a dividend?

    Yes. Qiagen NV pays $0.35 a share a year, a dividend yield of 0.70%.

    How much debt does QGEN have?

    Qiagen NV has $1.64B of total debt and $805.13M of cash and equivalents, a net debt position of $837.72M.